

[illegible]

1 of 3

Occult Blood	Negative	Negative	01
Bilirubin	Negative	Negative	01
Urobilinogen,Semi-Qn	0.2	0.0-1.9 mg/dL	01
Nitrite, Urine	Negative	Negative	01
Microscopic Examination	Comment		01
Microscopic not indicated and not performed.			
Lipid Panel			
Cholesterol, Total	206	HIGH	100-199 mg/dL 01
Triglycerides	49		0-149 mg/dL 01
HDL Cholesterol	63		>39 mg/dL 01
According to ATP-III Guidelines, HDL-C >59 mg/dL is considered a negative risk factor for CHD.			
VLDL Cholesterol Cal	10		5-40 mg/dL 01
LDL Cholesterol Calc	133	HIGH	0-99 mg/dL 01
Iron and TIBC			
Iron Bind.Cap.(TIBC)	310		250-450 ug/dL 01
UIBC	188		150-375 ug/dL 01
Iron, Serum	122		40-155 ug/dL 01
Iron Saturation	39		15-55 % 01
Testosterone,Free and Total			
Testosterone, Serum	310	LOW	348-1197 ng/dL 01
Comment:	Comment		01
Adult male reference interval is based on a population of lean males up to 40 years old.			
Free Testosterone(Direct)	7.0	LOW	8.7-25.1 pg/mL 02
Dihydrotestosterone			
Dihydrotestosterone	30		ng/dL 03
Reference Range: Adult Male: 30 - 85			
Hemoglobin A1c			
Hemoglobin A1c	4.9		4.8-5.6 % 01
Increased risk for diabetes: 5.7 - 6.4 Diabetes: >6.4 Glycemic control for adults with diabetes: <7.0			
Thyroxine (T4) Free, Direct, S			
T4,Free(Direct)	1.21		0.82-1.77 ng/dL 01
DHEA-Sulfate			
DHEA-Sulfate	242.3		102.6-416.3 ug/dL 01
TSH			
TSH	2.210		0.450-4.500 uIU/mL 01
Luteinizing Hormone(LH), S			
LH	4.6		1.7-8.6 mIU/mL 01
FSH, Serum			
FSH	2.1		1.5-12.4 mIU/mL 01
Prolactin			
Prolactin	10.8		4.0-15.2 ng/mL 01
Prostate-Specific Ag, Serum			
Prostate Specific Ag, Serum	0.6		0.0-4.0 ng/mL 01
Roche ECLIA methodology.			
According to the American Urological Association, Serum PSA should decrease and remain at undetectable levels after radical prostatectomy. The AUA defines biochemical recurrence as an initial PSA value 0.2 ng/mL or greater followed by a subsequent confirmatory PSA value 0.2 ng/mL or greater. Values obtained with different assay methods or kits cannot be used interchangeably. Results cannot be interpreted as absolute evidence of the presence or absence of malignant disease.			
IGF-1			
Insulin-Like Growth Factor I	230		83-233 ng/mL 02
C-Reactive Protein, Cardiac			
C-Reactive Protein, Cardiac	0.74		0.00-3.00 mg/L 01
Relative Risk for Future Cardiovascular Event			
Low		<1.00	

Average 1.00 - 3.00
High >3.00

Estradiol, Sensitive

Estradiol, Sensitive

5

3-70 pg/mL

02

	Male	Female
0- 6 yrs.	0 - 15	0 - 15
7-10 yrs.	0 - 15	0 - 70
11-12 yrs.	0 - 40	10 - 300
13-15 yrs.	0 - 45	10 - 300
>15 yrs.	3 - 70	See Below
Ovulating Female		
Follicular Phase		9 - 175
Luteal Phase		44 - 196
Periovulatory		107 - 281
Oral Contraceptives		0 - 91
Postmenopausal		
Treated		42 - 289
Untreated		0 - 19

Estradiol results obtained with different assay methods cannot be used interchangeably. It is recommended that only one assay method be used consistently to monitor serial patient results.

GGT			
GGT	21	0-65 IU/L	01
Magnesium, Serum			
Magnesium, Serum	2.0	1.6-2.6 mg/dL	01
Insulin			
Insulin	6.2	2.6-24.9 uIU/mL	01
Ferritin, Serum			
Ferritin, Serum	449	HIGH 30-400 ng/mL	01
Triiodothyronine,Free,Serum			
Triiodothyronine,Free,Serum	3.1	2.0-4.4 pg/mL	01
Sex Horm Binding Glob, Serum			
Sex Horm Binding Glob, Serum	32.3	16.5-55.9 nmol/L	01

[REDACTED]